AC Immune Statistics
Total Valuation
AC Immune has a market cap or net worth of $359.16 million. The enterprise value is $223.04 million.
Important Dates
The next estimated earnings date is Thursday, March 12, 2026, before market open.
| Earnings Date | Mar 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AC Immune has 98.94 million shares outstanding. The number of shares has increased by 4.26% in one year.
| Current Share Class | 98.94M |
| Shares Outstanding | 98.94M |
| Shares Change (YoY) | +4.26% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 2.99% |
| Owned by Institutions (%) | 4.85% |
| Float | 39.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 62.31 |
| Forward PS | 282.36 |
| PB Ratio | 4.38 |
| P/TBV Ratio | 23.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 40.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.16, with a Debt / Equity ratio of 0.07.
| Current Ratio | 1.16 |
| Quick Ratio | 1.12 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -408.24 |
Financial Efficiency
Return on equity (ROE) is -74.63% and return on invested capital (ROIC) is -45.59%.
| Return on Equity (ROE) | -74.63% |
| Return on Assets (ROA) | -21.97% |
| Return on Invested Capital (ROIC) | -45.59% |
| Return on Capital Employed (ROCE) | -99.66% |
| Revenue Per Employee | $31,878 |
| Profits Per Employee | -$524,035 |
| Employee Count | 172 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AC Immune has paid $3,762 in taxes.
| Income Tax | 3,762 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +34.53% in the last 52 weeks. The beta is 1.62, so AC Immune's price volatility has been higher than the market average.
| Beta (5Y) | 1.62 |
| 52-Week Price Change | +34.53% |
| 50-Day Moving Average | 3.18 |
| 200-Day Moving Average | 2.48 |
| Relative Strength Index (RSI) | 56.63 |
| Average Volume (20 Days) | 393,689 |
Short Selling Information
| Short Interest | 3.35M |
| Short Previous Month | 3.59M |
| Short % of Shares Out | 7.02% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.50 |
Income Statement
In the last 12 months, AC Immune had revenue of $5.48 million and -$90.13 million in losses. Loss per share was -$0.90.
| Revenue | 5.48M |
| Gross Profit | -71.77M |
| Operating Income | -91.64M |
| Pretax Income | -90.13M |
| Net Income | -90.13M |
| EBITDA | -89.86M |
| EBIT | -91.64M |
| Loss Per Share | -$0.90 |
Full Income StatementBalance Sheet
The company has $136.03 million in cash and $5.85 million in debt, with a net cash position of $130.19 million or $1.32 per share.
| Cash & Cash Equivalents | 136.03M |
| Total Debt | 5.85M |
| Net Cash | 130.19M |
| Net Cash Per Share | $1.32 |
| Equity (Book Value) | 78.31M |
| Book Value Per Share | 0.78 |
| Working Capital | 19.39M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$58.72 million and capital expenditures -$1.11 million, giving a free cash flow of -$60.38 million.
| Operating Cash Flow | -58.72M |
| Capital Expenditures | -1.11M |
| Free Cash Flow | -60.38M |
| FCF Per Share | -$0.61 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,671.43% |
| Pretax Margin | -1,643.82% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AC Immune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.26% |
| Shareholder Yield | -4.26% |
| Earnings Yield | -25.52% |
| FCF Yield | -17.09% |
Analyst Forecast
The average price target for AC Immune is $10.00, which is 175.48% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 175.48% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 46.56% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AC Immune has an Altman Z-Score of -3.57 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.57 |
| Piotroski F-Score | 1 |
